CompletedNCT03110432
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
Studying Rare hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GWT-TUD GmbH
- Principal Investigator
- David Pittrow, MD, PhDGWT-TUD GmbH, Germany
- Intervention
- PCSK9 Inhibitor [EPC](drug)
- Enrollment
- 1695 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2017 – 2024
Study locations (3)
- Klinik und Poliklinik für Kardiologie, Universitätsklinikum, Leipzig, Germany
- Innere Medizin IV - Diabetologie, Endokrinologie und Nephrologie am Universitaetsklinikum, Tübingen, Germany
- Nephrologisches Zentrum, Villingen-Schwenningen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03110432 on ClinicalTrials.govOther trials for Rare hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07470723The ORIGIN-FH StudyUniversity of Wisconsin, Madison
- RECRUITINGNANCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)Nantes University Hospital
- RECRUITINGPHASE2, PHASE3NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Merck Sharp & Dohme LLC
- RECRUITINGNCT06958315Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyNovartis Pharmaceuticals
- RECRUITINGNCT04529967Child-Parent Familial Hypercholesterolemia ScreeningChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT06597006Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- RECRUITINGNCT06634160Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial HypercholesterolemiaNantes University Hospital
- RECRUITINGPHASE3NCT06597019Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNovartis Pharmaceuticals